Rabies Veterinary Vaccines Market (By Application: Companion Animals, Livestock Animals, Wildlife Animals) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

The global rabies veterinary vaccines market was surpassed at USD 584.92 million in 2022 and is expected to hit around USD 868.33 million by 2032, growing at a CAGR of 4.03% from 2023 to 2032.

Report Highlights

• The companion animals segment dominated the global market with a revenue share of over 65.03% in 2022. 
• The wild animals segment is anticipated to expand at the fastest CAGR of 4.46% over the forecast period.
• North America dominated the market with a revenue share of over 25.05% in 2022. 

The key factors driving the market include an increase in zoonotic disease awareness, boosting stray animal immunization coverage, and growing number of government initiatives with the motive of eradicating rabies by 2030. One of the main drivers propelling the market for animal rabies vaccinations is domestic animal vaccine awareness and education. There are numerous vaccines approved for use in domestic animal species, which include inactivated and modified-live virus vector products, products for IM and SC injection, products with immunization durations ranging from 1 to 3 years, and products with a range of minimum vaccination ages. Regular public education, responsible pet ownership, routine veterinary treatment and vaccinations, and continuous professional training are crucial elements of rabies prevention and control. By spreading knowledge about rabies transmission channels, the necessity of avoiding contact with wildlife and vaccinating wildlife with bait rabies vaccines are widely initiated, which greatly helps in reducing the spread of the disease from wildlife sources. Additionally, the vaccination improves domestic animals’ general health and is linked to a decline in all-cause mortality rates.

Rabies is a deadly disease that attacks the central nervous system and has no effective treatment once clinical signs appear. It is estimated that 8.6 million dollars are spent globally on canine rabies, which is responsible for 98% of approximately 60,000 total rabies deaths that occur each year. The U.S. has made enormous efforts over the past 50 years to eradicate rabies in both animal and human populations. The number of animals infected with canine-mediated rabies has decreased from up to 10,000 cases per year because of the development of mass animal vaccination procedures and the enforcement of leash restrictions. Despite these developments, rabies continues to pose a major threat to public health and is still prevalent in raccoons, skunks, and foxes in wildlife reservoirs throughout the U.S.

All around the world, the COVID-19 pandemic has disrupted crucial health services. The United Against Rabies Forum, which advocates a ‘One Health’ strategy, was established in 2020 to hasten the achievement of this objective. The main components of the global rabies strategy include community involvement, better access to human rabies vaccines, and expanded mass dog vaccination. The advancement of rabies eradication strategies can be used as a marker for the equity of healthcare access in underserved populations and as an early indicator for the successful implementation of ‘One Health’. The core element of the global rabies elimination strategy is mass dog vaccination, with a 70% coverage rate as the goal. The majority of endemic nations saw difficulties with distribution, volume reductions, and importation delays for dog vaccines. This was because dog vaccines initially did not fit within the category of necessary items. Budget restrictions prevented the production of dog vaccines even in countries such as Zambia where they are made locally.

Rabies is spread through saliva, which means the infection can be transmitted through infected animal bites. Rabies can be transmitted by monkeys, dogs, bats, or, in some cases, cats. 98% of rabies cases in Indonesia are caused by rabid dog bites. According to an article published in December 2021, by the National Library of Medicine over the past 10 years, there has been a slight increase in the number of animal rabies cases globally. In Thailand, a study was conducted between 2017 and 2018 to identify the characteristics of animal rabies, assess the relationship between monthly rabies incidence and understandable factors using generalized additive models, and estimate the geographical risk areas for rabies spread. According to the study, dogs are the most common species in Thailand that are infected by rabies. The majority of the infected dogs were owned, roaming freely, and were not vaccinated. The northeast region of the country has the highest concentrations of rabies cases, followed by the middle and southern regions. In the short term, the number of cases increased gradually after June and significantly from January in 2018. Such rabies-endemic countries are taking strong measures such as dog mass vaccination programs, wildlife bait rabies vaccination campaigns, and mandatory pet rabies vaccinations among others, which are anticipated to fuel the growth of the market.

Application Insights

The companion animals segment dominated the global market with a revenue share of over 65.03% in 2022. Nearly 98% of rabies transmission in several parts of the world is caused by the infected dog population. The rabies virus can incubate in any mammal for days to months without definitive clinical signs, therefore limiting the timely treatments. This devastating viral infection causes severe inflammation in the brain leading usually to death. The only way of protecting pet animals and owners is by getting a regular rabies vaccination and boosters. Considering the major impact of this zoonotic neuroinvasive infection, many countries have mandated rabies vaccination for companion animals, which supports the estimated revenue share.

The wild animals segment is anticipated to expand at the fastest CAGR of 4.46% over the forecast period owing to the rising wildlife rabies vaccination campaigns in developed regions. According to the Centers for Disease Control & Prevention, wild animals were responsible for 92.7% of U.S. rabies cases registered in 2018. Raccoons (30.3%), skunks (20.3%), foxes (7.2%), and bats (33%) were the most commonly reported wild rabid species. Variants of the rabies virus remain spread within the species to which they have been widely adopted. Similarly, raccoons, foxes, skunks, and mongooses have rabies virus variations that are concentrated in specific geographical areas.

For instance, in every state of the U.S. besides Hawaii, rabid bats were reported between 2013 and 2022. In some areas of California, Texas, the Midwest, Virginia, North Carolina, Kentucky, and Tennessee, rabies-carrying skunks have been commonly identified. The South and Eastern states have reported finding rabid raccoons. There have been cases of rabid foxes in Alaska, Arizona, and New Mexico. Moreover, in Texas, Arizona, and New Mexico, rabies-carrying foxes and skunks have been found; whereas, in Puerto Rico, rabies-carrying mongooses have been seen.

According to an article published by the Centers for Disease Control and Prevention, domestic dogs no longer serve as a rabies reservoir in the United States due to the implementation of mandated canine vaccination programs that have stopped the disease's natural transmission among them. Nevertheless, each year, reports of rabid animals range from 60 to 70 canines to over 250 cats. Almost all of these animals lacked vaccinations and contracted rabies from wild animals (such as bats, raccoons, and skunks).

Regional Insights

North America dominated the market with a revenue share of over 25.05% in 2022. This can be attributed to the presence of a large pet population with respectively high veterinary healthcare expenditure. In addition, well-established veterinary pharmaceutical companies and government organizations are striving for the wide implementation of mass vaccination programs and oral wildlife rabies bait-vaccine campaigns to augment rabies eradication measures. The increasing pet humanization trends and awareness among pet owners to prevent fatal infections such as rabies in their beloved animals are further improving the vaccination coverage of the region.

Asia Pacific held the second-largest share in 2022 and is anticipated to grow at the fastest rate during the forecast period. Rabies is one of the major public health concerns in Southeast Asian countries. China, India, and most ASEAN countries are reported to be endemic for canine rabies with significantly higher rabies-related cases each year. The large presence of the stray dog population is a major reason for the disease burden in Asia. Recently, the region has initiated several strategies to eradicate rabies by 2030, such as the implementation of mass dog vaccination programs in collaboration with key players and government organizations. For instance, as a part of the rabies control initiative, Global Alliance for Rabies Control (GARC) and Boehringer Ingelheim have organized a mass rabies vaccination program in April 2022 to vaccinate 12,000 animals across the Philippines, Indonesia, Vietnam, and Malaysia. These factors are significantly contributing to the market growth.

Key Players

• Merck & Co., Inc. (MSD Animal Health)
• Indian Immunologicals Ltd.
• Boehringer Ingelheim International GmbH (Animal Health)
• Zoetis
• Virbac
• BroadChem Philippines Biopharma Corporation
• Elanco
• Ceva
• BiogénesisBagó

Market Segmentation

• By Application Outlook
• Companion Animals
• Livestock Animals
• Wildlife Animals
• By Regional Outlook
• North America

• U.S.

• Canada

• Europe

• Poland

• Russia

• Romania

• Turkey

• Spain

• Asia Pacific

• China

• Japan

• India

• South Korea

• Thailand

• Latin America

• Brazil

• Mexico

• Argentina

• Middle East & Africa

• South Africa

• South Arabia

• UAE